Advisor Pro analyzes patient data from continuous glucose monitoring, self-monitoring blood glucose and insulin pump devices to generate personalized insulin delivery recommendations. These recommendations are meant to help healthcare providers manage treatment for patients with Type 1 diabetes.
The FDA decision marks DreaMed Diabetes’ second regulatory approval this year. The company received the European Union’s CE Mark in February.
More articles on supply chain:
4 latest FDA approvals
Almost two-thirds of consumers think product recalls are just ‘red tape’
Flex Pharma to slash 60% of workforce, consider sale or merger
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.